![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Characterization of Resistance in HCV Genotype 1b-Infected Japanese and Western Patients Treated With an Interferon- and Ribavirin-Free Regimen of Ombitasvir and Paritaprevir/Ritonavir
|
|
|
Reported by Jules Levin
APASL 2015
24th Conference of the Asian Pacific Association for the Study of the Liver (APASL), 12-15 March 2015, Istanbul, Turkey
Tami Pilot-Mati as1, Gretja Schnell1, Rakesh Tripathi1, Thomas Reisch1, Jill Beyer1, Preethi Krishnan1, Liangjun Lu1,
Teresa Ng1, Lino Rodrigues-Jr1, Carolyn Setze1, Xinyan Zhang1, Coleen Hall1, Regis A Vilchez1, Christine Collins1,
Christophe Hezode2, Kazuaki Chayama3, Hiromitsu Kumada4
1AbbVie Inc., North Chicago, Illinois, United States; 2Department of Hepatology and Gastroenterology, H™pital Henri Mondor, AP-HP, Universitˇ Paris-Est,
INSERM U955, Crˇteil, France; 3Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan; 4Department of Hepatology,
Toranomon Hospital, Tokyo, Japan
![APASL1.gif](../images/031815/031815-4/APASL1.gif)
![APASL2.gif](../images/031815/031815-4/APASL2.gif)
![APASL3.gif](../images/031815/031815-4/APASL3.gif)
![APASL4.gif](../images/031815/031815-4/APASL4.gif)
![APASL5.gif](../images/031815/031815-4/APASL5.gif)
![APASL6.gif](../images/031815/031815-4/APASL6.gif)
![APASL7.gif](../images/031815/031815-4/APASL7.gif)
![APASL8.gif](../images/031815/031815-4/APASL8.gif)
![APASL9.gif](../images/031815/031815-4/APASL9.gif)
![APASL10.gif](../images/031815/031815-4/APASL10.gif)
![APASL11.gif](../images/031815/031815-4/APASL11.gif)
![APASL12.gif](../images/031815/031815-4/APASL12.gif)
![APASL13.gif](../images/031815/031815-4/APASL13.gif)
![references.gif](../images/031815/031815-4/references.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|